Since joining Novo Nordisk UK in 2018, Sahota has guided the UK team through key milestones, contributing to unprecedented growth
Pinder Sahota has announced his resignation as General Manager UK at Novo Nordisk after serving in the role for seven years.
In a LinkedIn post, Sahota reflected on his time with the company, saying, “As I prepare to step away from my role at Novo Nordisk, I am filled with a deep sense of gratitude and reflection.
“What began as a job evolved into an unforgettable experience, driven by a mission that inspired me daily and the privilege of collaborating with exceptional individuals.”
Regarding his next steps, Sahota mentioned that he would help the new GM transition into the role and take some time to “recharge and explore new opportunities where I can make a meaningful contribution.”
During his tenure, Sahota led the UK team through significant milestones, including five product launches, delivery of numerous clinical trials, navigating supply challenges, and responding to the impacts of a global pandemic.
He also worked under three managers and two governments, guiding the company through a period of unprecedented growth.
He praised the resilience and dedication of the UK team, stating, “Managing each of these milestones has been a testament to the resilience, ambition, and unwavering commitment of the UK team that defines the Novo Nordisk way.”
Although Sahota is excited about the new opportunities that lie ahead, he admitted, “It doesn’t make it any easier to leave behind such an extraordinary team” while expressing his appreciation to his colleagues for their support and knowledge sharing.
Sahota has over two decades of healthcare experience in senior commercial and leadership roles across Europe. Previously he was responsible for developing the commercial & market development strategy for key brands across Europe in his role as senior vice president of market and commercial development for Europe at Smith & Nephew based in Baar, Switzerland.
While serving as general manager at Novo Nordisk UK, he also held positions as chair of the CBI Health Council and president of the Association of the British Pharmaceutical Industry (ABPI).
A passionate advocate for reducing health inequalities, fostering collaboration within the pharmaceutical industry, and promoting sustainable patient care and environmental responsibility, Sahota leaves behind a legacy of dedication and impactful leadership at Novo Nordisk.
